ChengDa Pharmaceuticals Co., Ltd. (SHE:301201)

ChengDa Pharmaceuticals Revenue

ChengDa Pharmaceuticals had revenue of 127.25M CNY in the quarter ending June 30, 2026, with 19.88% growth. This brings the company's total for the last twelve months to 479.41M, up 36.36% year-over-year. In the year 2025, ChengDa Pharmaceuticals had annual revenue of 406.37M with 21.99% growth. That makes ChengDa Pharmaceuticals the 25,210th largest company in the world by revenue and 4,488th in China.

• Revenue (ttm): 479.41M
• Revenue Growth: +36.36%
• P/S Ratio: 8.03
• Revenue / Employee: 690.79K
• Employees: 694
• Market Cap: 3.85B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• China 260.24M 64.0%
• Foreign 146.13M 36.0%

Fiscal year ended Dec 31, 2025 See the full ChengDa Pharmaceuticals breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	406.37M	73.24M	21.99%
Dec 31, 2024	333.13M	-81.17M	-19.59%
Dec 31, 2023	414.30M	2.84M	0.69%
Jan 1, 2023	411.46M	-4.26M	-1.03%
Jan 1, 2022	415.73M	42.69M	11.44%

Data Source: S&P Global Market Intelligence Last updated: Aug 25, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 21, 2026

Data Sources Report a data error